Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jul 11;17(2):273–287. doi: 10.22074/cellj.2016.3730

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig.4 — Effects of VEGF-siRNA and/or doxorubicin treatment on growth and colony formation in Hep3B cells. A. Cell viability of Hep3B cells treated with VEGF-siRNA or CONT-siRNA for five days in WST-1 assay. Cell viability is expressed as the percentage of control cells (or medium), B. Hep3B cells treated with the indicated concentration of doxorubicin at a specified time in the WST-1 assay. Results are presented as the inhibitory ratio of doxorubicin treated cells, C, D, E. Hep3B cells treated with VEGF-siRNA/CONT-siRNA in combination with the indicated concentration of doxorubicin for specified time. Inhibition was determined by the WST-1 assay and F. Effects of VEGF-siRNA and/or doxorubicin treatment on the inhibition of cell proliferation were confirmed by the cloning efficiency. Each bar represents the mean value ± standard deviation (SD) of triplicate experiments. *; P<0.05, **; P<0.01 compared to the control cell group (medium) for A, B and F or doxorubicin alone treated cell group for C, D, E, #; P<0.05 compared to the VEGF-siRNA treated cell group, Dox 0; 0 μg/ml (or medium) doxorubicin, Dox 1; 1 μg/ml doxorubicin, Dox 2; 2 μg/ml doxorubicin, Dox 4; 4 μg/ml doxorubicin, VEGF-siRNA; Vascular endothelial growth factor targeted small-interfering RNA and CONT-siRNA; Mismatched small-interfering RNA.